The Role of Fc-FcγR Interactions in IgG-mediated Microbial Neutralization

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 2015 Aug 19

PMID 26282878

Citations 91

Authors

Stylianos Bournazos

David J DiLillo

Jeffrey V Ravetch

Affiliations

Soon will be listed here.

Abstract

Antibodies are bifunctional molecules, containing a variable Fab domain that mediates binding specificity and a constant Fc domain that bridges antibody-coated targets with FcγR-expressing cells that mediate effector functions. Although traditional mechanisms of antibody-mediated neutralization of microbes have been largely thought to result from Fab-antigen interactions, recent studies suggest that recruitment of FcγR-expressing effector cells by antibodies is a major in vivo mechanism of antibody-mediated protection from infection. In this article, we review FcγR biology, compare mammalian FcγR families, and summarize recent evidence demonstrating the crucial role that Fc-FcγR interactions play during in vivo protection from infection.

Citing Articles

Progress and Challenges in HIV-1 Vaccine Research: A Comprehensive Overview.

Boomgarden A, Upadhyay C Vaccines (Basel). 2025; 13(2).

PMID: 40006695 PMC: 11860913. DOI: 10.3390/vaccines13020148.

A multi-antigen vaccinia vaccine broadly protected mice against SARS-CoV-2 and influenza A virus while also targeting SARS-CoV-1 and MERS-CoV.

Gao N, Yang T, Dong L, Tang W, Cao K, Ding L Front Immunol. 2024; 15:1473428.

PMID: 39669563 PMC: 11634893. DOI: 10.3389/fimmu.2024.1473428.

Probiotic bacteria-released extracellular vesicles enhance macrophage phagocytosis in polymicrobial sepsis by activating the FPR1/2 pathway.

Zhu R, Zhang Y, Wang X, Liu B, Chowdhury D, Li Z Mol Med. 2024; 30(1):216.

PMID: 39543493 PMC: 11566284. DOI: 10.1186/s10020-024-00959-9.

TMT-proteomics reveals the therapeutic effects of Lianling decoction against atopic dermatitis through infection.

Zhang L, Fan Z, Li L, Sun Z Heliyon. 2024; 10(19):e38381.

PMID: 39403467 PMC: 11471467. DOI: 10.1016/j.heliyon.2024.e38381.

Fc-FcγR interactions during infections: From neutralizing antibodies to antibody-dependent enhancement.

Edgar J, Bournazos S Immunol Rev. 2024; 328(1):221-242.

PMID: 39268652 PMC: 11659939. DOI: 10.1111/imr.13393.

References

Tan G, Krammer F, Eggink D, Kongchanagul A, Moran T, Palese P . A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J Virol. 2012; 86(11):6179-88. PMC: 3372189. DOI: 10.1128/JVI.00469-12. View

Bournazos S, Hart S, Chamberlain L, Glennie M, Dransfield I . Association of FcgammaRIIa (CD32a) with lipid rafts regulates ligand binding activity. J Immunol. 2009; 182(12):8026-36. DOI: 10.4049/jimmunol.0900107. View

Simek M, Rida W, Priddy F, Pung P, Carrow E, Laufer D . Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol. 2009; 83(14):7337-48. PMC: 2704778. DOI: 10.1128/JVI.00110-09. View

Anthony R, Ravetch J . A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol. 2010; 30 Suppl 1:S9-14. DOI: 10.1007/s10875-010-9405-6. View

Qiu W, de Bruin D, Brownstein B, Pearse R, Ravetch J . Organization of the human and mouse low-affinity Fc gamma R genes: duplication and recombination. Science. 1990; 248(4956):732-5. DOI: 10.1126/science.2139735. View

DiLillo D, Ravetch J . Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect. Cell. 2015; 161(5):1035-1045. PMC: 4441863. DOI: 10.1016/j.cell.2015.04.016. View

Corti D, Voss J, Gamblin S, Codoni G, Macagno A, Jarrossay D . A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011; 333(6044):850-6. DOI: 10.1126/science.1205669. View

Nimmerjahn F, Ravetch J . Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science. 2005; 310(5753):1510-2. DOI: 10.1126/science.1118948. View

Halper-Stromberg A, Lu C, Klein F, Horwitz J, Bournazos S, Nogueira L . Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell. 2014; 158(5):989-999. PMC: 4163911. DOI: 10.1016/j.cell.2014.07.043. View

10.

Fiebiger B, Maamary J, Pincetic A, Ravetch J . Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs. Proc Natl Acad Sci U S A. 2015; 112(18):E2385-94. PMC: 4426441. DOI: 10.1073/pnas.1505292112. View

11.

Burton D, Ahmed R, Barouch D, Butera S, Crotty S, Godzik A . A Blueprint for HIV Vaccine Discovery. Cell Host Microbe. 2012; 12(4):396-407. PMC: 3513329. DOI: 10.1016/j.chom.2012.09.008. View

12.

Mascola J, Stiegler G, Vancott T, Katinger H, Carpenter C, Hanson C . Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med. 2000; 6(2):207-10. DOI: 10.1038/72318. View

13.

Bournazos S, Klein F, Pietzsch J, Seaman M, Nussenzweig M, Ravetch J . Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell. 2014; 158(6):1243-1253. PMC: 4167398. DOI: 10.1016/j.cell.2014.08.023. View

14.

Clynes R, Towers T, Presta L, Ravetch J . Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000; 6(4):443-6. DOI: 10.1038/74704. View

15.

Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D . Diversity considerations in HIV-1 vaccine selection. Science. 2002; 296(5577):2354-60. DOI: 10.1126/science.1070441. View

16.

Balazs A, Chen J, Hong C, Rao D, Yang L, Baltimore D . Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature. 2011; 481(7379):81-4. PMC: 3253190. DOI: 10.1038/nature10660. View

17.

Bournazos S, Chow S, Abboud N, Casadevall A, Ravetch J . Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity. J Clin Invest. 2014; 124(2):725-9. PMC: 3904629. DOI: 10.1172/JCI72676. View

18.

Schwab I, Nimmerjahn F . Intravenous immunoglobulin therapy: how does IgG modulate the immune system?. Nat Rev Immunol. 2013; 13(3):176-89. DOI: 10.1038/nri3401. View

19.

Qiu X, Audet J, Wong G, Fernando L, Bello A, Pillet S . Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci Rep. 2013; 3:3365. PMC: 3842534. DOI: 10.1038/srep03365. View

20.

Caskey M, Klein F, Lorenzi J, Seaman M, West Jr A, Buckley N . Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015; 522(7557):487-91. PMC: 4890714. DOI: 10.1038/nature14411. View